Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)

Cancer Chemotherapy and Pharmacology
Kiyoshi YoshinoTadashi Kimura

Abstract

To develop a new therapeutic strategy for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancers, we evaluated the feasibility and efficacy of irinotecan and gemcitabine combination chemotherapy. Patients with taxane/platinum-resistant/refractory cancer received escalating doses of irinotecan and gemcitabine (level 1: 80 and 800 mg/m2, respectively; level 2: 100 and 1000 mg/m2) on days 1 and 8 on a 21-day cycle. Genotyping for UGT1A1*6 and *28 polymorphisms was performed for possible adverse irinotecan sensitivity. A total of 35 patients were enrolled. The recommended dose was defined as 100 mg/m2 irinotecan and 1000 mg/m2 gemcitabine (level 2). The observed common grade 3/4 toxicities were neutropenia (60%), anemia (17.1%), diarrhea (8.6%), thrombocytopenia (5.7%) and nausea (5.7%). Groups homozygous for UGT1A1*6 or *28 were associated with grade 3/4 neutropenia and diarrhea. Objective responses were 20%, including one complete response and six partial responses. In 29 patients treated with the recommended dose, the median progression-free survival and overall survival were 3.8 months (95% CI 2.1-6.0 months) and 17.4 months (95% CI 9.9-21.9 months), respectively, while the 1-year survival rate was 58.6%. C...Continue Reading

References

Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio Max S Rocha LimaMark R Green
Feb 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G P StathopoulosUNKNOWN Greek Cooperative Group for Pancreatic Cancer
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Jun 26, 2004·Oncology·Sofia AgelakiUNKNOWN Lung Cancer Subgroup, Hellenic Oncology Research Group
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ji-Youn HanJin Soo Lee
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J O'Dwyer, Robert B Catalano
Jun 30, 2007·Japanese Journal of Clinical Oncology·Hiroshi TakataniUNKNOWN Nagasaki Thoracic Oncology Group
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G MutchAngeles Alvarez Secord
Mar 12, 2009·Gynecologic Oncology·Muneaki ShimadaTsunehisa Kaku
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeRobert J Mayer
Sep 8, 2010·Expert Opinion on Investigational Drugs·Koji MatsuoAnil K Sood
Dec 14, 2011·Gynecologic Oncology·Marcela G del CarmenJohn O Schorge
Feb 9, 2013·International Journal of Clinical Oncology·Hiroaki KajiyamaFumitaka Kikkawa
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
Feb 11, 2016·Asia-Pacific Journal of Clinical Oncology·Masashi TakanoYuh Sakata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.